June 22, 2020 / 1:05 PM / in a month

BRIEF-Myovant Sciences Announces FDA Acceptance Of New Drug Application For Prostate Cancer Treatment

June 23 (Reuters) - Myovant Sciences Ltd:

* MYOVANT SCIENCES ANNOUNCES PRIORITY REVIEW AND FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ONCE-DAILY, ORAL RELUGOLIX FOR ADVANCED PROSTATE CANCER

* MYOVANT SCIENCES LTD - PRIORITY REVIEW STATUS EXPECTED TO ACCELERATE REVIEW, WITH A TARGET FDA ACTION DATE OF DECEMBER 20, 2020

* MYOVANT SCIENCES LTD - DATA FROM AN ADDITIONAL KEY SECONDARY ENDPOINT, CASTRATION RESISTANCE-FREE SURVIVAL, ARE EXPECTED IN Q3 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below